Nisa Investment Advisors LLC Sells 8,095 Shares of DexCom, Inc. (NASDAQ:DXCM)

Nisa Investment Advisors LLC trimmed its holdings in DexCom, Inc. (NASDAQ:DXCM) by 11.8% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 60,365 shares of the medical device company’s stock after selling 8,095 shares during the period. Nisa Investment Advisors LLC’s holdings in DexCom were worth $4,047,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Team Hewins LLC increased its holdings in shares of DexCom by 3.4% during the 1st quarter. Team Hewins LLC now owns 2,555 shares of the medical device company’s stock valued at $354,000 after acquiring an additional 83 shares during the last quarter. Bleakley Financial Group LLC raised its position in shares of DexCom by 1.3% in the first quarter. Bleakley Financial Group LLC now owns 6,856 shares of the medical device company’s stock valued at $951,000 after purchasing an additional 87 shares during the period. Capital Insight Partners LLC lifted its stake in shares of DexCom by 2.5% in the second quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company’s stock worth $418,000 after buying an additional 90 shares during the last quarter. HM Payson & Co. boosted its holdings in shares of DexCom by 6.0% during the 1st quarter. HM Payson & Co. now owns 1,780 shares of the medical device company’s stock worth $247,000 after buying an additional 100 shares during the period. Finally, Clear Creek Financial Management LLC grew its stake in DexCom by 4.2% in the 2nd quarter. Clear Creek Financial Management LLC now owns 2,961 shares of the medical device company’s stock valued at $336,000 after buying an additional 120 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Buying and Selling at DexCom

In other DexCom news, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the transaction, the executive vice president now owns 75,451 shares of the company’s stock, valued at $5,217,436.65. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.30% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. JPMorgan Chase & Co. boosted their target price on shares of DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Leerink Partners decreased their target price on DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Sanford C. Bernstein lifted their price target on DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. Robert W. Baird increased their price objective on DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a research report on Monday, August 5th. Finally, Baird R W downgraded shares of DexCom from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 26th. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $104.59.

DexCom Trading Down 0.2 %

DXCM stock opened at $70.35 on Friday. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The firm has a market cap of $27.48 billion, a P/E ratio of 42.13, a P/E/G ratio of 2.20 and a beta of 1.18. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The business’s 50 day moving average is $69.85 and its 200-day moving average is $95.92.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.